


TheraPEP® Positive Expiratory Pressure Therapy System Improving Quality of Life



RESPIRATORY CARE



PORTEX



The TheraPEP® System is the Proven Choice for Secretion Clearance and Reversal of Atelectasis^{1, 2}

TheraPEP® PEP Therapy System is the easy-to-use system for mobilising secretions in patients with Cystic Fibrosis (CF), lung diseases with secretory problems and to prevent or reverse atelectasis, as well as patients recovering from surgery. Unlike labour-intensive, time-consuming chest physiotherapy (CPT), Positive Expiratory Pressure (PEP) Therapy with TheraPEP® PEP Therapy System can be self-administered by the patient in any setting, in less than half the time required for CPT.

Product Features:

- Six Fixed Orifice Options.
- Built-in durable pressure indicator.
- 22mm OD patient end.
- Inspiratory valve.

Product Benefits:

- Can accommodate virtually any patient's lung capacity.
- Resists breakage, unlike fragile, costly manometers.
- Provides immediate, visual 360° feedback of prescribed pressure.
- May be used with a mask or mouthpiece, or Nebuliser.
- Allows inhalation and exhalation without removing from mouth.

TheraPEP® POSITIVE EXPIRATORY PRESSURE THERAPY SYSTEM

	Chest Percussion Therapy (CPT)	TheraPEP® Positive Expiratory
Effectiveness:	Promotes secretion mobilisation through postural drainage, percussion, or vibration.	Improves secretion clearance, facilitates opening of airways, and effectively reverses atelectasis.
Tolerance:	May exacerbate dyspnea in post-surgical and endstage Cystic Fibrosis patients, ³ cause pain, or bruising.	May reduce need for postural drainage.
Labour/Time:	A single Chest Percussion Therapy session can last up to one hour; patients may require up to four sessions daily.	Can be performed in less than half the time of a conventional Chest Percussion Therpay session. ³
Restrictions:	Requires private environment, assistance of second person, and scheduling around daily activities.	Helps patient maintain effective continuum of care outside the hospital.
Aerosol Therapy:	Must be performed separately.	Clinicians can do two treatments in the time of one.



Simultaneous aerosol drug delivery with MDI spacer while performing therapy for secretion clearance and atelectasis.



Simultaneous aerosol drug delivery with nebuliser while performing therapy for secretion clearance and atelectasis.



Patient administered secretion clearance and reversal atelectasis.

Designed for positive expiratory pressure therapy and simultaneous aerosol drug delivery, the TheraPEP® System can help virtually any patient with secretory problems mobilise secretions easily, conveniently, and cost-effectively.

PEP therapy, unlike CPT, can be self-administered, helping patients maintain an effective continuum of care outside the hospital. The TheraPEP® System may reduce the need for postural drainage and percussion, and can be performed in less than half the time of a

conventional CPT session. ³ This offers significant time savings for both patients and clinicians.

The TheraPEP® System is even more efficient when used with a medication nebuliser or MDI spacer. The patient can receive aerolised medication, and perform therapy for secretion clearance and atelectasis, in the time of one treatment. PEP therapy may also optimise delivery of bronchodilators in patients receiving bronchial hygiene therapy. ⁴ No other secretion clearance device offers you a better combination of therapy, flexibility, and efficiency.

- McIlwaine PM, Wong LT, Peacock D, Davidson GF. Longterm comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr. October 1997.
- Protocol of the Month, University of Pittsburgh Medical Center, Department of Respiratory Care. AARC Times, May 1997.
- 3. Mahlmeister MJ, Fink JB, Hoffman GL, Fifer LF.

 "Positive-expiratory-pressure mask therapy: Theoretical and Practical Considerations and a Review of the Literature", Respiratory Care, 1991;36:1218-1230.
- 4. "AARC Clinical Practice: 'Use of Positive Airway Pressure Adjuncts to Bronchial Hygiene Therapy'," Respiratory Care, 1993;38:516-521.

TheraPEP®

ORDERING INFORMATION				
Product Code	PRODUCT DESCRIPTION	UNITS/CASE		
20-1112	TheraPEP® System with Mouthpiece	10		
20-3112	TheraPEP® System with Paediatric Mask	1		
20-5112	TheraPEP® System with Small Mask	1		
20-7112	TheraPEP® System with Large Mask	1		

ACCESSORIES				
Product Code	PRODUCT DESCRIPTION	UNITS/CASE		
20-3115	Paediatric Mask	1		
20-5115	Small Adult Mask	1		
20-7115	Large Adult Mask	1		
20-0005	Connector, Straight, 22 mm I. D.	10		
20-0010	TheraPEP® Pressure Port	10		
20-0022	TheraPEP® Pressure Port, Tubing, Indicator	10		
20-0050	TheraPEP® Mouthpiece 22 mm I. D.	50		
20-0120	TheraPEP® Pressure Port and Resistor	10		
20-1110	TheraPEP® Pressure Port, Resistor and Mouthpiece	10		
20-0004	Gauge Guard	20		

All TheraPEP $^{\odot}$ Systems Include: Pressure Port, Resistor, 22 mm ID Straight Connector, Tubing and Pressure Indicator.









For further information please visit: www.smiths-medical.com/respiratorycare

THE DETAILS GIVEN IN THIS LEAFLET ARE CORRECT AT THE TIME OF GOING TO PRESS. THE COMPANY RESERVES THE RIGHT TO IMPROVE THE EQUIPMENT SHOWN.

Smiths Medical International Ltd

Hythe, Kent CT21 6JL UK

Tel: +44 (0)1303 260551 Fax: +44 (0)1303 266761

Smiths Medical ASD, Inc.

160 Weymouth Street

Rockland, MA 02370 (USA)

Tel: (800) 848-1757 Fax: (800) 621-2950

www.smiths-medical.com

Smiths Medical, part of the global technology business Smiths Group

The Smiths Medical and Portex design marks; and TheraPEP are trademarks of the Smiths Medical family of companies. The symbol ® indicates the trademark is registered in the U.S. Patent and trademark office and certain other countries. Literature No. LIT/AM3006

smiths medical